Diamyd Medical
18.48
SEK
+2.67 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+2.67%
+12.41%
+22.87%
+31.62%
+31.06%
+160.65%
+24.52%
+3.77%
+512.59%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Read moreMarket cap
1.92B SEK
Turnover
8.27M SEK
Revenue
130K
EBIT %
-112,746.15 %
P/E
-
Dividend yield-%
-
Financial calendar
29.1
2025
Interim report Q1'25
9.4
2025
Interim report Q2'25
25.6
2025
Interim report Q3'25
ShowingAll content types
Diamyd Medical AB: Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical's Scientific Advisory Board
Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools